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Abstract 
 Immune deficiency disorders are a heterogeneous group of diseases of variable genetic 
aetiology. Whilst the hallmark of immunodeficiency is susceptibility to infection, it is increasingly 
clear that autoimmunity is prevalent suggestive of a more general immune dysregulation in 
some cases. With the increasing use of genetic technologies the underlying causes of immune 
dysregulation are beginning to emerge. Here we provide a review of the heterozygous 
mutations found in the immune checkpoint protein CTLA-4, which was originally identified in 
cases of Common Variable Immunodeficiency Disorders (CVID) with accompanying 
autoimmunity. Study of these mutations provides insights into the biology of CTLA-4 as well as 
suggesting approaches for rational treatment of these patients. 
 
 
Biology of the CTLA-4 pathway 
 
The CTLA-4 pathway can be thought of as an integrated system involving two opposing 
receptors CD28 (stimulatory) and CTLA-4 (inhibitory). CTLA-4 and CD28 are transmembrane 
proteins expressed predominantly by T lymphocytes that interact with two shared ligands, CD80 
and CD86, found on antigen presenting cells (Figure 1). The two ligands differ in both 
expression pattern and interaction affinities, however there is still limited data on how they might 
differentially affect immune function. In line with their relatively small size and their role in 
regulating T cell responses, both CD28 and CTLA-4 can be found interacting with their ligands 
at the immune synapse, where the higher affinity CTLA-4 interactions can compete with CD28 
for ligand binding[1, 2].  
 
Whereas CD28 is found at the plasma membrane on T cells, CTLA-4 expression is more 
complex. CTLA-4 is induced following activation of conventional T cells and is constitutively 
expressed by Treg. Approximately 10% of CTLA-4 is expressed at the membrane at any given 
time, with 90% occupying a variety of intracellular compartments. This is as a result of CTLA-4 
being internalized via endocytosis, due to the presence of a “YVKM” motif in its cytoplasmic tail 
[3].  This motif interacts constitutively with the clathrin adaptor AP-2 resulting in rapid 
internalization of CTLA-4, in the absence of ligand binding[4]. Internalization exposes CTLA-4 to 
both re-cycling and degradation within the cell and it is becoming increasingly clear that correct 
trafficking is critical to its function. 
 
Whilst CTLA-4 internalisation is not well understood, it is nonetheless in keeping with the ability 
of CTLA-4 to carry out a process, termed transendocytosis(TE)[5]. Here CTLA-4 binds its 
ligands at the plasma membrane and subsequently internalises them resulting in their removal 
from the APC. This results in APCs that have impaired expression of ligands and are therefore 
unable to stimulate T cells through CD28. Such a process potentially explains why CD28 and 
CTLA-4 share ligands and is consistent with a mechanism whereby CTLA-4 is highly expressed 
by Treg and can suppress T cell responses in a cell-extrinsic manner. 
 
In summary, CD28 and CTLA-4 are functionally opposing receptors expressed by T cells, which 
interact with the same ligands but with differing affinities and cell biology. These interactions 
play a central role in balancing both effective immune responses to pathogens as well as 
regulating autoimmune responses against self-tissues. 
 
The Immunology of CTLA-4 and CD28. 
It is increasingly apparent that thymic selection fails to remove all self-reactive T cells [6, 7], 
resulting in significant numbers of potentially autoimmune T cells in the circulation of healthy 
individuals. Not only is the TCR repertoire highly cross reactive, making tolerance by deletion 
difficult [8] but autoreactive T cells appear to be present at frequencies similar to other antigen 
specificities [9], arguing deletion is incomplete. Additional levels of control of T responses (and 
subsequently B cell responses) to self-antigens are therefore required and it is here that the 
CTLA-4 receptor is of critical importance [10-12].  It is now established that complete loss of 
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CTLA-4 in mice causes fatal autoimmunity within ~3 weeks of birth [13, 14] demonstrating a 
key, non-redundant role for CTLA-4 in preventing autoimmune responses. Furthermore, the 
description of humans carrying CTLA-4 mutations and suffering from profound autoimmunity 
[15, 16] suggests that the autoimmune protective effects of CTLA-4 are evolutionarily 
conserved. Similarly, anti-CTLA-4 antibodies used to block CTLA-4 function in the cancer 
setting can be thought of as treatment-induced autoimmunity against tumour antigens[17]. 
Taken together these data argue unequivocally that CTLA-4 is an essential regulator of immune 
responses to our own tissues. 
 
In contrast, to CTLA-4, CD28 provides signals that enhance T cell activation and is widely 
recognised as the archetypal “co-stimulatory” receptor, alongside the TCR. Since CD28 ligands 
are upregulated by inflammatory signals such as those following Toll-like receptor recognition, 
CD28 signalling represents  “danger” in the context of antigen recognition, driving T cell 
activation, differentiation and effector function [18]. Thus CD28 engagement by its ligands on 
antigen presenting cells is responsive to inflammation, providing a direct connection between 
the innate and adaptive immune systems. Interestingly one of the major functions of CD28 
costimulation is to facilitate help for B cells via the generation of Tfh cells.  Accordingly in the 
absence of CD28, class switched antibody responses are virtually absent[19], germinal centers 
are impaired [20] and even heterozygous loss at the CD28 locus impacts on B cell 
responses[21]. A second major feature of the requirement for CD28 costimulation is in the 
generation and survival of regulatory T cells. Accordingly, in situations where CD28 
costimulation is prevented, for example in mice lacking CD28 or its ligands,or in the presence of 
ligand blockade [22-24] [25] there is an accompanying loss of Treg. Thus, CD28 signalling 
drives the generation of effector T cell responses, is critical for class-switched antibody 
generation and supports homeostasis of Treg whilst CTLA-4 opposes these. Together, these 
features highlight the delicate balance, which is the hallmark of the CD28 / CTLA-4 pathway. 
 
Whilst the costimulatory function of CD28 is relatively clear, the biological function of CTLA-4 
has been more difficult to discern. What is beyond doubt is that CTLA-4 is a negative regulator 
of T cell responses. Furthermore, CTLA-4 is needed to oppose CD28 function, since inhibiting 
CD28 in mice can prevent disease caused by CTLA-4 deficiency and increasingly, such 
concepts appear to be replicated in humans.  Exactly how CTLA-4 functions at the molecular 
level remains controversial, with discussion focusing on cell-intrinsic (e.g. signaling) vs cell-
extrinsic (e.g. regulatory) mechanisms [10-12, 26-28]. Whilst it was initially proposed that CTLA-
4 generated inhibitory signals that prevented TCR signaling (cell intrinsic effects), experimental 
evidence now appears to favour the view that the major CTLA-4 functions are T cell-extrinsic 
and necessary for the effective function of regulatory T cells[29-32]. For example, in mixed 
bone-marrow chimeric mice CTLA-4-/- T cells behave indistinguishably from CTLA-4+/+ [33-35] 
indicating that CTLA-4+/+ cells can extrinsically control the behaviour of CTLA-4-/- T cells in a 
“regulatory” manner. These concepts become significant when it comes to investigating the 
impact of CTLA-4 deficiency in patients and how to determine defective CTLA-4 function.  
 
The idea that CTLA-4 on T cells acts extrinsically to regulate the behavior of other T cells, is in 
keeping with the TE model of CTLA-4 function. Here CTLA-4 acts as a competitor for CD28 
stimulation by physically removing their shared ligands from APCs [5] (Figure 2),consistent with 
CTLA-4 as an effector mechanism for Treg suppressive activity. However, a number of other 
models have also been proposed including inhibitory signalling, triggering of tryptophan 
metabolism and effects on T cell motility (see[11, 26-28] for reviews). Currently, the actual 
mechanisms critical to CTLA-4 function in vivo remain to be formally established.  
 
 
Identification of CTLA-4 deficiency and clinical features 
Overactivity of the immune system resulting in autoimmune and inflammatory complications is a 
well-recognized paradox in Primary immunodeficiency (PID) disorders[36]. For example, in 
addition to antibody deficiency, a spectrum of immune dysregulation is seen in CVID, which 
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includes, but is by no means limited to B-cell and auto-antibody mediated conditions. 
Lymphocytic infiltration and granuloma formation, particularly involving gut, lung and liver are 
hallmarks of such associated immune dysregulation and likely to involve multiple immune 
lineages. Recently, loss of function mutations in CTLA-4 have emerged, mainly from cohorts of 
patients diagnosed with antibody deficiency and severe immune dysregulation[16] [15] providing 
insight into the pathogenesis of immune dysregulation in a subset of patients.  
 
Schubert et.al. investigated a large kindred with 5 family members affected by 
hypogammaglbulinaemia, recurrent respiratory tract infections, autoimmune cytopenia, 
autoimmune enteropathy and infiltrative lung disease (who were found to have heterozygous 
mutations in CTLA-4 [15]. Genetic analysis revealed the same CTLA-4 mutation in 6 other 
family members considered to be healthy. Based on clinical phenotype, other families with CVID 
and enteropathy or autoimmunity were investigated revealing 5 additional index patients with 
novel CTLA-4 mutations, 3 asymptomatic mutation ‘carriers’ and a further 4 patients based on 
family history.   
 
Another study[16], reported 9 patients with CTLA-4 mutations across 4 unrelated families with a 
history of hypogammaglobulinaemia, CD4+ T cell lymphopenia, autoimmune cytopenias and 
lymphocytic infiltration. Of these, six individuals were clinically symptomatic with three reportedly 
healthy.  Additional sporadic cases have been reported [37-40] and a further 8 patients with 
CTLA-4 mutations who underwent stem cell transplantation have also been described [41]. 
Similar clinical features were reported in most cases, as well as additional complications that 
extend the spectrum of disease including autoimmune hepatitis, primary sclerosing cholangitis, 
pure red cell aplasia, adrenal insufficiency, type I diabetes, arthritis, and autoimmune 
choirodopathy. 
 
The reported clinical features of CTLA-4 deficiency described to date are summarized in Table 
1. With the exception of recurrent upper and lower respiratory tract infections, almost all relate 
to immune dysregulation and autoimmunity. Splenomegaly and lymphadenopathy are common 
and extensive CD4+ T cell organ infiltration can be seen in multiple organs, including the 
intestine, lung, bone marrow, central nervous system and kidney. Although opportunistic 
infections do not appear to be a prominent feature, one patient was diagnosed with CMV 
gastritis prior to development of gastric carcinoma [39] albeit following steroid treatment. 
Malignancy risk appears to be elevated with 3 patients developing gastric carcinoma and two 
Hodgkin’s lymphoma. It is not known yet if currently classified asymptomatic/healthy patients 
progress at a later stage and this will be an important question for follow up studies. 
 
Reduced immunoglobulin levels were noted in most symptomatic patients with heterozygous 
CTLA-4 mutations [15, 16]. This was associated in the majority of individuals with a low or 
progressively falling percentage of CD19+ B cells, a low percentage of switched memory B-cells 
and a predominance of CD21lo B-cells, which are thought to represent exhausted B-cells 
producing lower levels of immunoglobulin in vitro.  In addition, there is evidence of excessive T-
cell activation indicated by low levels of naive T-cells and elevated expression of the surface 
molecule PD-1 (Programmed cell death protein 1). FOXP3+ (forkhead box P3) regulatory T-
cells are present at normal or even higher percentages but these express low levels of CTLA-4 
and function poorly [42]. Conventional T-cell proliferation and in vitro T-cell differentiation are 
preserved. 
 
The majority of mutations in CTLA-4 affect the CTLA-4 extracellular domain(Figure 3). 
However, there does not appear to be a clear genotype-phenotype correlation and incomplete 
clinical penetrance has not been fully explained.  Additional factors including genetic and 
epigenetic modifiers, microbial exposure or environmental factors may therefore influence the 
clinical outcome of CTLA-4 deficiency. It is interesting to note that bi-allelic loss of function 
mutations in LRBA (lipopolysaccharide responsive beige-like anchor protein) result in a 
phenocopy disease with autosomal recessive inheritance and severe early onset [43]. It is now 
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known that CTLA-4 requires LRBA for regulation of its intracellular trafficking, so that loss of 
LRBA expression effectively reduces CTLA-4 expression, resulting in functional CTLA-4 
deficiency[44]. 
 
 
 
Lessons from CTLA-4 deficiency in humans 
 
The fact that CTLA-4 deficiency results in highly variable features of autoimmunity appears to 
result from inappropriate activation of polyclonal T cells. This maybe observed clinically in that 
generally these patients have expanded populations of memory T cells. Thus whilst 
presentation of disease is highly variable it is consistent with the concept of increased CD28 
costimulation triggering self-reactive T cells against a variety of tissues. Similarly in CTLA-4-
deficient mice, T cells are seen to infiltrate multiple tissues and to recognize autoantigens[13, 
14, 45]. It may be significant that many of the sites worst affected, eg. Gut, lungs and skin are 
also sites where there is an interface with the microbiome, where the levels of costimulatory 
molecules on APCs may be higher. 
 
A key feature of CTLA-4 deficiency in humans is the impact on the regulatory T cell 
compartment.  Consistent with a T cell-extrinsic role for CTLA-4, a Treg functional deficiency is 
observed in these patients, with an impaired ability to suppress T cell proliferation [15, 16]. This 
defect relates to impaired CTLA-4 function since suppression in these experiments is abrogated 
by anti-CTLA-4 antibody[15]. In addition, decreased ability of Treg from CTLA-4 mutation 
carriers (both clinically affected and unaffected) to carry out transendocytosis or to uptake 
soluble CTLA-4 ligands was also observed [42]. Since Treg express the highest levels of CTLA-
4 it may be that deficiency in one allele is sufficient to compromise the high levels of expression 
required for effective function. 
 
Given the role of CD28 in Treg homeostasis[25, 46, 47] it might be expected that Treg 
proportions are affected in CTLA-4 deficiency. Mice deficient in CTLA-4 show marked 
expansions in Treg numbers due to the increased availability of CD28 signalling[48] and similar 
expansions are seen in a number of CTLA-4 deficient patients. It should be noted that Treg 
analysis is frequently confounded by the low expression of CD25, which is seen in many CVID 
patients, and precludes the use of CD25 as a marker for Treg. However we have observed that 
Foxp3 staining, particularly following a brief stimulation, reveals that Treg numbers are generally 
normal or elevated in these patients with some individuals displaying very marked 
expansions[42]. 
 
Whilst the impact of CTLA-4 deficiency on Treg biology is clear, its effects on activated T cells, 
which also express CTLA-4 are more difficult to determine. It has been suggested that 
conventional CD4 and CD8 T cells in individuals with CTLA-4 mutations can be 
hyperproliferative[16] [38, 49]. However, this has not been our experience and such 
experiments require careful set up and interpretation. We have previously shown CTLA-4 plays 
little if any intrinsic role in regulating the proliferation of human CD4 T cells[50] and nor is CTLA-
4 function readily measured in assays where CD3/CD28 antibodies are used as a stimulus. 
Given that patients with CTLA-4 deficiency often have a preponderance of activated and 
memory T cells in their blood, direct comparisons with control samples are confounded unless 
this is corrected for. Thus further studies are needed andit is not yet clear that in vitro 
hyperproliferation of conventional T cells is a direct consequence or a useful measure of CTLA-
4 deficiency. 
 
 
Treatment options for CTLA-4 deficiency 
 
Management of patients with CTLA-4 deficiency requires attention to both the immunodeficiency 
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and immune dysregulation features of disease. Immunoglobulin replacement therapy, with or 
without prophylactic antibiotics, represents the main conservative management approach for 
infection prophylaxis. However, given that CTLA-4 deficiency is in essence a T cell 
hyperactivation disorder, immunosuppressive compounds are frequently required, despite the 
potential for worsening immunodeficiency. Given the rare nature of the condition, there are no 
agreed treatment guidelines for managing the associated immune dysregulation and very little 
evidence for long-term response to different immunosuppressive agents that could be used to 
rationalize drug selection. 
 
In CTLA-4 deficiency, limited information from case reports indicates that that corticosteroids 
have been the most consistently utilised immunosuppressive for autoimmune cytopoenias, 
enteropathy, infiltrative lung disease and CNS inflammation [15, 16]. Reported responses are 
variable and the need for high dose and recurrent doses of steroids is apparent. A number of 
steroid sparing agents have also been employed including sirolimus in multiple patients, 
rituximab, MMF, Cyclosporin A, anti-thymocyte globulin, anti-TNF drugs and vedoluzimab, with 
improvement in some but not all cases [15, 16] [37, 38]. Even for individual patients, some 
features of immune dysregulation may respond to a given drug while other complications remain 
resistant. The need for recurrent, multiple and serial steroid sparing agents in CTLA-4 deficiency 
highlights the severity of immunopathology in this condition as well as the inadequacy of current 
treatment approaches. 
 
Abatacept, a CTLA-4-immunoglobulin fusion protein licensed for the treatment of rheumatoid 
arthritis[51], holds promise as a more rational and targeted approach to treatment. Since 
abatacept is a soluble version of CTLA-4 itself it may be considered as a CTLA-4 replacement 
therapy. Additional experience has been published for use of Abatacept to treat infiltrative lung 
disease in LRBA deficiency with an improvement in the clinical status, HRCT chest radiological 
appearances and pulmonary function tests in 3 patients using a dosing regime of 20 mg/kg 
every 2-4 weeks for up to 8 years[44]. Chronic norovirus was observed in two of the patients but 
otherwise there were minimal infectious with no deterioration in lung disease whilst on 
treatment. In that study an additional 3 patients commenced Abatacept for gastrointestinal 
disease with reported improvement in 2/3 over a short follow up of less than 6 months on 
treatment, with up to 30mg/kg dosing 2 weekly. To date, there are only two instructive published 
reports of Abatacept use in CTLA-4 deficiency. In one case, an unspecified dose of Abatacept 
was used for autoimmune choroidopathy with good response within 3 months [40]. In the 
second case, treatment was instigated for enteropathy and autoimmune hemolytic anemia 
(dose 10mg/kg two weekly) with good response and no reported side effects [49]. In addition, 
sustained remission over several months was achieved with a maintenance dose of 5mg/kg 
monthly. It is still not clear whether Abatacept is sufficient as a sole long-term 
immunosuppressive agent for patients with CTLA-4 deficiency and future trials should also 
consider Belatacept which is a similar molecule with a higher ligand affinity, currently in trial for 
prevention of renal transplant rejection(https://clinicaltrials.gov). 
Haematopoetic stem cell transplantation (HSCT) has been used as a treatment strategy for life 
threatening, treatment resistant immune dysregulation in CTLA-4 deficiency[41]. 8 patients with 
severe clinical disease were transplanted with an age range of 10 - 32 years. 6 were alive and 
well in April 2016 (3.5mo, 4mo, 2yr, 4yr, 4.75yr and 10.2yr post transplant respectively), one 
with ongoing sirolimus for resolving chronic GvHD. In total GHVD was seen in 4 patients, and 
led to death in one case. A second patient died two and half years post-transplant from diabetic 
ketoacidosis.  These results are encouraging and demonstrate that CTLA-4 deficiency can be 
potentially cured by HSCT, although GVHD risk may be higher because of the inflammatory 
burden at transplantation making autologous gene therapy approaches an attractive proposition 
for the future.  
Conclusions 
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CTLA-4 deficiency is a novel PID that joins the growing subset of inherited immunodeficiencies 
associated with prominent autoimmunity and immune dysregulation. It is evident that Treg 
dysfunction is a key mechanism of the immune activation associated with CTLA-4 loss of 
function mutations although the cellular causes of immunodeficiency remain unclear. The 
availability of pathway-specific treatments that provide a soluble form of CTLA-4 hold promise 
for targeted therapy and highlight the importance of gene discovery to improve treatment for PID 
presenting outside, as well as during, childhood. Finally, lessons learnt from CTLA-4 in PID 
have application for other common autoimmune diseases and potentially cancer 
immunotherapy. 
 
 
The authors have no competing financial interests.  
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Table1: Main clinical features associated with confirmed CTLA-4 mutations. 
 
Lung: 
- Granulomatous Lymphocytic Interstital Lung Disease (infiltrative lung disease) 
- Fibrosis 
- Bronchiectasis 
Cytopenias: 
- Autoimmune Haemolytic anaemia 
- Autoimmune thrombocytopenia 
- Autoimmune Neutropenia 
Gut: 
- Diarrhoea/Enteropathy 
- Gastric cancer  
Autoimmunity: 
- Type 1 diabetes 
- Autoimmune thyroiditis 
- Arthritis 
- Psoriasis  
- Uveitis 
- Vitiligo 
- Myasthenia gravis. 
Others: 
- Lymphadenopathy 
- Splenomegaly 
- Lymphocytic infiltration of non lymphoid organs (Lung, bone marrow, gut, brain) 
- Malignancy 
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Figure	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Figure 1. Interactions between CD28, CTLA-4 and their natural ligands. Cartoons shows the “immune synapse 
between a CTLA-4-expressing T cell or Treg and an APC expressing the two ligands CD80 and CD86. The affinity of 
the interactions is depicted from right to left with the lowest interaction CD86-CD28 on the left and the highest CD80-
CTLA-4 on the right.  
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Figure 2. Mechanism of action for CTLA-4. A Regulatory T cell (Treg) expressing CTLA-4 can capture and internalise 
stimulatory ligands (CD86 shown) by transendocytosis. Ligands are internalised into the CTLA-4 expressing cell and 
degraded whilst CTLA-4 is recycled. This results in reduction of available CD86 and therefore loss of CD28 
costimulatory signals in the responder T cell (Tresp). This mechanism is compatible with much of the biology of 
CTLA-4 but is not exclusive of other mechanisms. 
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Figure 3. Schematic view of reported CTLA-4 mutations. DNA mutations are shown in the upper half of the diagram 
and aligned with amino acid changes below. The alignment between exons and protein functional domains is 
shown.Mutations are color coded according to the report in which they are described. 
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